Create Account | Sign In: Author or Forum

News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
Category: Neurology | Pathology | Journal

Back to Journal Articles

Transcription Profile Distinguishes Subgroups in MS

Last Updated: September 26, 2012.

Patients with multiple sclerosis can be differentiated according to their transcription profile, according to a study published online Sept. 26 in Science Translational Medicine.


Patients in subgroup MSA more likely to have a new inflammatory event during treatment

Share |

Comments: (0)




WEDNESDAY, Sept. 26 (HealthDay News) -- Patients with multiple sclerosis (MS) can be differentiated according to their transcription profile, according to a study published in the Sept. 26 issue of Science Translational Medicine.

Linda Ottoboni, R.N., from the Brigham and Women's Hospital in Boston, and colleagues examined the structure of an MS patient population using a transcriptional profile generated from peripheral blood mononuclear cells.

Among 141 untreated patients, the researchers identified two subsets of MS patients (MSA and MSB). This structure was replicated in two additional groups of patients with MS, one treated with glatiramer acetate (94 patients) and the second treated with interferon-β (128 patients). Higher expression of molecules involved in lymphocyte signaling pathways was seen in subgroup MSA. In addition, patients in subgroup MSA were significantly more likely to experience a new inflammatory event while on treatment with glatiramer acetate or interferon-β.

"Overall, we report a transcriptional signature that distinguishes a subset of MS patients with more active disease," the authors write. "Stratifying MS subjects into meaningful subsets in this manner has potential for personalizing patient care and for enhancing our understanding of this disease."

Two authors disclosed financial ties to the pharmaceutical industry. Affymetrix Inc. produced the RNA data.

Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.

Previous: Short-, Long-Course Therapy Comparable in T3 Rectal Cancer Next: Myogenes Identified for Spondyloarthritis Synovitis

Reader comments on this article are listed below. Review our comments policy.

Submit your opinion:





Remember my personal information

Notify me of follow-up comments?


Useful Sites
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2016
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.